Selective signaling via unique M1 muscarinic agonists

Ann N Y Acad Sci. 1993 Sep 24:695:300-3. doi: 10.1111/j.1749-6632.1993.tb23070.x.


Rigid analogs of acetylcholine (ACh) were designed for selective actions at muscarinic receptor (mAChR) subtypes and distinct second messenger systems. AF102B, AF150, and AF151 are such rigid analogs of ACh. AF102B, AF150 and AF151 are centrally active M1 agonists. AF102B has a unique agonistic profile showing, inter alia: only part of the M1 electrophysiology of ACh and unusual binding parameters to mAChRs. AF150 and AF151 are more efficacious agonists than AF102B for M1 AChRS in rat cortex and in CHO cells stably transfected with the m1 AChR subtype. Notably, the selectivity of the new m1 agonists is reflected also by activation of select second messenger systems via distinct G-proteins. These compounds reflect a new pharmacological concept, tentatively defined as ligand-selective signaling. Thus, agonist/m1AChR complexes may activate different combinations of signaling pathways, depending on the ligand used. Rigid agonists may activate a limited repertoire of signaling systems. In various animal models for Alzheimer's disease (AD) the agonists AF102B, AF150 and AF151, exhibited positive effects on mnemomic processes and a wide safety margin. Such agonists, and especially AF102B, can be considered as a rational treatment strategy for AD.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acetylcholine / analogs & derivatives*
  • Acetylcholine / chemical synthesis
  • Acetylcholine / pharmacology*
  • Alzheimer Disease / physiopathology
  • Animals
  • CHO Cells
  • Cricetinae
  • Drug Design
  • Humans
  • Parasympathomimetics / chemical synthesis
  • Parasympathomimetics / pharmacology*
  • Receptors, Muscarinic / biosynthesis
  • Receptors, Muscarinic / drug effects
  • Receptors, Muscarinic / physiology*
  • Signal Transduction*
  • Transfection


  • Parasympathomimetics
  • Receptors, Muscarinic
  • Acetylcholine